EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.
Andrew X. Zhu
Consultant or Advisory Role - Daiichi Sankyo; Eisai; Sanofi
Research Funding - Bayer; ImClone Systems; Lilly; Novartis; Onyx
Masatoshi Kudo
Consultant or Advisory Role - Novartis
Eric Assenat
Consultant or Advisory Role - Novartis
Stéphane Cattan
No relevant relationships to disclose
Yoon-Koo Kang
Consultant or Advisory Role - Bayer; Novartis; Roche; Sanofi
Research Funding - Bayer; Novartis; Roche; Sanofi
Ho Yeong Lim
No relevant relationships to disclose
Ronnie Tung Ping Poon
Consultant or Advisory Role - Novartis
Jean-Frédéric Blanc
No relevant relationships to disclose
Arndt Vogel
No relevant relationships to disclose
Chao-Long Chen
No relevant relationships to disclose
Etienne Dorval
No relevant relationships to disclose
Markus Peck-Radosavljevic
Consultant or Advisory Role - ArQule (U); Bayer Schering Pharma (U); Boehringer Ingelheim (U); Daiichi Sankyo (U)
Honoraria - Abbott Laboratories; Bayer Schering Pharma; Lilly; Novartis
Research Funding - Bayer Schering Pharma
Armando Santoro
No relevant relationships to disclose
Bruno Daniele
Consultant or Advisory Role - Bayer; Daiichi Sankyo
Honoraria - Bayer; Daiichi Sankyo; Novartis
Junji Furuse
Honoraria - Novartis
Annette Jappe
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Kevin Perraud
Employment or Leadership Position - Novartis
Ozlem Anak
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Dalila B. Sellami
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Li-Tzong Chen
Honoraria - Novartis
Research Funding - Novartis